Embla Medical hf (EMBLA.CO,OSSFF,OSSUY), a provider of medical products and equipment, on Tuesday reported an increase in earnings and sales for the fourth quarter.
Sveinn Sölvason, CEO of Embla Medical, said: "We delivered solid sales in the fourth quarter amounting to USD 257 million. Organic sales growth was 7% and 10% in local currency including contribution from the majority investment in Streifeneder ortho.production, which was completed in September 2025. Growth in the quarter was driven by Prosthetics & Neuro Orthotics, supported by continued strong growth momentum in EMEA and recently launched innovation. Sales in Patient Care picked up in Q4 with a strong finish to the year."
For the three-month period, the company posted a net profit of $24.404 million, or 5.8 cents per share, higher than $18.207 million, or 4.4 cents per share, in the same period last year. Earnings before interest and tax stood at $32.438 million as against the prior year's $31.867 million.
The company reported sales of $256.691 million, up from $224.781 million in the previous year. The Prosthetics & Neuro Orthotics segment reported sales of $141 million, up 19% from last year.
Looking ahead, for fiscal 2026, Embla Medical expects organic sales growth of 5% to 8%, helped by strong volume growth in the core business with moderate price increases. The company anticipates an annual adjusted EBITDA margin of 20% to 22%, driven by scale and efficiency coupled with continued focus on cost control in SG&A.
For fiscal 2025, Embla Medical registered organic sales growth of 6% with an adjusted EBITDA margin of 20%.
Embla Medical will release its annual report on February 3.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.